drugset / Trial / NCT05283395
Rocklatan® Evaluation
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
Timeline
- Start
- 2022-03-28
- Primary completion
- 2023-03-22
- Completion
- 2023-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution | Unknown | 0.005 % | Topical |
| Subject | Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution | Unknown | 0.02 % | Topical |